نتایج جستجو برای: resistance to i 131 therapy

تعداد نتایج: 11251683  

Journal: :European journal of endocrinology 2009
M Chianelli V Todino F M Graziano C Panunzi D Pace R Guglielmi A Signore E Papini

OBJECTIVE (a) To compare the efficacy of low-activity (2 GBq; 54 mCi) (131)I ablation using l-thyroxine withdrawal or rhTSH stimulation, and (b) to assess the influence of thyroid remnants volume on the ablation rate. DESIGN Patients underwent neck ultrasound, (131)I neck scintigraphy and radioiodine uptake. Post-therapy whole body scan (WBS) was acquired after 4-6 days. Ablation was assessed...

Journal: :Thyroid : official journal of the American Thyroid Association 2014
Stephanie Markovina Perry W Grigsby Julie K Schwarz Todd DeWees Jeffrey F Moley Barry A Siegel Stephanie M Perkins

BACKGROUND Well-differentiated thyroid carcinoma in children and adolescents is a rare disease with favorable prognosis despite regional and distant metastasis at presentation in many patients. Treatment recommendations are varied and there is little consensus on follow-up guidelines for these patients. METHODS Medical records of patients less than 22 years of age treated at our institution w...

Journal: :research in molecular medicine 0
reza valadan molecular and cell biology research center, faculty of medicine, mazandaran university of medical sciences, sari, iran alireza rafiei molecular and cell biology research center, faculty of medicine, mazandaran university of medical sciences, sari, iran mohsen tehrani molecular and cell biology research center, faculty of medicine, mazandaran university of medical sciences, sari, iran forough nejatollahi recombinant antibody laboratory, department of immunology, faculty of medicine, shiraz university of medical sciences, shiraz, iran

production and approval of trastuzumab (herceptin®) for the treatment of metastatic breast cancer (mbc) was a millstone in antibody-based targeted therapy in the cancer treatment. however, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. the majority of patients who benefit from the drug acqui...

2015
Jianfei Huang Qi Tang Changjun Wang Huixin Yu Zhenqing Feng Jin Zhu

Vascular endothelial growth factor receptor 2 (VEGFR2) is traditionally regarded as an important therapeutic target in a wide variety of malignancies, such as hepatocellular carcinoma (HCC). We previously generated a murine-human anti-VEGFR2 chimeric Fab (cFab), named FA8H1, which has the potential to treat VEGFR2-overexpressing solid tumors. Here, we investigated whether FA8H1 can be used as a...

Journal: :Environmental Health Perspectives 1998
G. Hooker H. Durbin

Tumour-associated monoclonal antibodies (HMFG1, HMFG2 and AUAI) radiolabelled with iodine-131 were given intracavitary (intrapleurally and intrapericardially) to patients with malignant effusions. Ten out of 13 effusions (3 pericardial and 7 pleural) responded completely with no fluid reaccumulation between 3 and 18 months. No clinical or other toxicity was observed. This new method of treatmen...

Journal: :Hellenic journal of nuclear medicine 2012
Hong-Jun Song Yan-Li Xue Zhong-Ling Qiu Quan-Yong Luo

Differentiated thyroid carcinoma (DTC) usually behaves in an indolent manner with low metastatic potential. The major sites of distant metastases are the lung and bone. Metastases to the brain, eye, breast, liver, kidney, muscle and skin are rare or relatively rare. These metastases have almost always appeared in patients with advanced disease and are often associated with poor prognosis but ov...

Journal: :Medicinski arhiv 2009
Rubina Alimanovic-Alagic Elma Kucukalic-Selimovic Mevludin Mekic

Thyroid gland is the largest endocrine gland in the body. The thyroid gland produces hormones that regulate the metabolism rate, affect the growth and many functions of various organ systems. Nuclear medicine technique is very useful diagnostic tool in detecting thyroid disease. Thyroid scintigraphy can reveal functional and anatomic information of thyroid gland. A variety of radiopharmaceutica...

2017
Jonathan Wadsley Rebecca Gregory Glenn Flux Kate Newbold Yong Du Laura Moss Andrew Hall Louise Flanagan Sarah R Brown

Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in resensitizing advanced iodine refractory differentiated thyroid cancer to radioiodine therapy...

Journal: :British medical journal 1980
D J Handelsman A J Conway P E Donnelly J R Turtle

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید